Traumatic Stress Network

Mission statement/aims

Memories for emotionally arousing and stressful events are retained well in general. From an evolutionary point of view this is beneficial since it prepares individuals for future threats. An extreme example of retention of these events occurs in posttraumatic stress disorder (PTSD), which is characterized by persistent vivid and inappropriate memories of traumatic situations. These events can be life threatening situations such as military combat, natural disasters, terrorist incidents, serious accidents, or violent personal assaults which significantly impair the person's daily activities. Despite efforts to develop more effective therapies, PTSD remains a difficult disorder to treat. There is currently no effective medication for the treatment of PTSD, pharmacotherapy is used for symptom management.

Recent studies, both in experimental animals and humans, demonstrate that memories for emotionally arousing events become labile upon retrieval. More specifically, the molecular machinery that is required for consolidation of arousing information needs to be activated in order to store the information (reconsolidation). A major implication is that targeting the process of reconsolidation offers a highly relevant approach to pharmacologically target the expression of fearful and traumatic memories.

Two windows of opportunity that can be defined as ‘golden hours’ can be identified: event-based golden hours and exposure-based golden hours. The first are defined by the traumatic event, and subsequent consolidation of the traumatic event. The second is determined by the setting in which exposure as a therapeutic tool is introduced and the subsequent reconsolidation phase.

There are currently several compounds that are used in preclinical studies to target systems or receptors which are fundamental for consolidation and reconsolidation. While this offers an enormous opportunity to target these emotions, and there is some validation from clinical studies, there is currently a lack in the translational on a wider scale between fundamental and clinical scientists to optimally use the capitalize knowledge form the different domains.
The main topics that will be studied are:

  • History of Psychopharmacology for Traumatic Stress; Where do we come from?
  • The Vulnerable Phenotype; Evidence from Molecular Biology
  • ‘Golden’ Hours opportunities; Targets and Research Design
  • (Re)consolidation of Traumatic Memories: Mechanisms and Translational Issues
  • Guidelines for Rational Pharmacotherapy for Disorders related to Traumatic Stress Exposure

In particular we ask:

  • When can trauma related memories be treated? (‘golden’ hours)
  • Which mechanisms can be used to target (consolidation and reconsolidation)
  • What determines vulnerability and resilience (gene and environment interaction)


The network consist of experts from different European countries that can warrant and optimize use of existing knowledge in basic, clinical and pharmacological domains. The Stress related TNM has initiated NATO workshop application that will be submitted early 2016. Moreover, the Stress related TNM is eager to identify new grant opportunities (ERANET, HORIZON 2020, NATO, etc.) and collaborate towards proposal submissions.

Additional groups interested in Traumatic Stress will be added to the core group.